There are currently 10 active clinical trials seeking participants for Bleeding research studies. The states with the highest number of trials for Bleeding participants are Texas, California, New York and Florida.
Quantra Point-of-Care Hemostasis Monitoring
NCT06328647
Recruiting
The investigators will test the hypothesis that utilization of a blood and blood component transfusion algorithm guided by the POC Quantra QPlus System in patients undergoing complex cardiac surgery will reduce RBC, plasma, cryoprecipitate, and platelet transfusion during surgery and the first 12 postoperative hours, compared to standard of care (central laboratory transfusion monitoring at the primary anesthesia provider's discretion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Bleeding, Hemostatic Disorder
Register for Updates
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: CHI St. Vincent, Arkansas, Little Rock, Arkansas +95 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: University Hospital - Univ. of Alabama at Birmingham (UAB), Birmingham, Alabama +131 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Obsidio™ Conformable Embolic Registry
NCT06170619
Recruiting
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +19 locations
Conditions: Hypervascular Tumors, Bleeding, Hemorrhage
Register for Updates
SIMPLAAFY Clinical Trial
NCT06521463
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Tucson Medical Center Healthcare, Tucson, Arizona +16 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients with Assist Device
NCT06655376
Recruiting
Heart failure is a world epidemic. LVADs are increasingly used as they have demonstrated improved survival rates compared to optimal medical management. Improving outcomes have been seen with the newer LVAD technology, the HeartMate 3 (Abbott, Chicago, IL), however, hemocompatibility related adverse events, including thrombosis and bleeding, are still a major cause of morbidity and mortality. The recent ARIES trial showed that in patients with advanced heart failure treated with a HeartMate3 LVA... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Columbia Irving Medical Center, New York, New York
Conditions: Bleeding, Clot Blood
Register for Updates
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
NCT04598750
Recruiting
This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.
Gender:
ALL
Ages:
1 day and above
Trial Updated:
10/07/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +7 locations
Conditions: Neonatal Thrombocytopenia, Bleeding
Register for Updates
Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial
NCT06549842
Recruiting
The Safe and Fast Radial Hemostasis using Synergistic Strategies (SAFE \& FAST) trial is an interventional study aimed at reducing the incidence of radial artery occlusion (RAO) rebound bleeding, and the required compression time after transradial approach (TRA) procedures, which have become the default access for coronary procedures globally. The hypothesis is that combining lower-dose heparin and radial hemostasis with simultaneous ipsilateral ulnar artery compression could achieve these i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Regional Hospital of Scranton, Scranton, Pennsylvania
Conditions: Cardiovascular Diseases, Bleeding, Arterial Puncture, Catheter Complications, Occlusion of Artery
Register for Updates
Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects
NCT06000423
Recruiting
This randomized double blinded trial seeks to determine whether tranexamic acid (TXA) is an efficacious treatment for contraceptive induced menstrual changes (CIMC) including irregular, bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (ENG implant). Participants will be randomized into the TXA treatment arm or a placebo. They will begin taking the medication after three consecutive days of bleeding. Participants will track their bleeding using an automated text mess... Read More
Gender:
Female
Ages:
Between 15 years and 45 years
Trial Updated:
04/01/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Bleeding, Contraceptive Device; Complications
Register for Updates
Extended Cold Stored Apheresis Platelets in Cardiac Surgery Patients
NCT05220787
Recruiting
This trial is being performed to evaluate the feasibility of the study protocol and to test the efficacy and safety of platelets stored at cold conditions (1-6°C) in 100% plasma for 10-14 days (CSP) in cardiac surgery patients who are actively bleeding and require platelet transfusion.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
07/26/2023
Locations: Swedish Medical Center - Cherry Hill, Seattle, Washington
Conditions: Hemorrhage, Platelets; Defect, Bleeding, Surgical Blood Loss
Register for Updates